These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24795391)

  • 1. An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
    Oshima J; Hisama FM; Martin GM
    Circulation; 2014 Jul; 130(1):4-6. PubMed ID: 24795391
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
    Gordon LB; Massaro J; D'Agostino RB; Campbell SE; Brazier J; Brown WT; Kleinman ME; Kieran MW;
    Circulation; 2014 Jul; 130(1):27-34. PubMed ID: 24795390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development for progeria yields insights into normal aging.
    Jiang K
    Nat Med; 2013 May; 19(5):515. PubMed ID: 23652088
    [No Abstract]   [Full Text] [Related]  

  • 6. Prelamin A prenylation and the treatment of progeria.
    Worman HJ
    J Lipid Res; 2010 Feb; 51(2):223-5. PubMed ID: 19965579
    [No Abstract]   [Full Text] [Related]  

  • 7. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome.
    Blondel S; Jaskowiak AL; Egesipe AL; Le Corf A; Navarro C; Cordette V; Martinat C; Laabi Y; Djabali K; de Sandre-Giovannoli A; Levy N; Peschanski M; Nissan X
    Stem Cells Transl Med; 2014 Apr; 3(4):510-9. PubMed ID: 24598781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejuvenating premature aging.
    Meshorer E; Gruenbaum Y
    Nat Med; 2008 Jul; 14(7):713-5. PubMed ID: 18607367
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
    Cubria MB; Suarez S; Masoudi A; Oftadeh R; Kamalapathy P; DuBose A; Erdos MR; Cabral WA; Karim L; Collins FS; Snyder BD; Nazarian A
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12029-12040. PubMed ID: 32404427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.
    Fong LG; Frost D; Meta M; Qiao X; Yang SH; Coffinier C; Young SG
    Science; 2006 Mar; 311(5767):1621-3. PubMed ID: 16484451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
    Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
    Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
    Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
    Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
    Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
    FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progeria: case report and new drugs perspectives.
    Grana AG; Silva AA; Moura Filho FR; Rodrigues Ferreira Rocha de Alencar R; Chicre Bandeira de Melo P
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e293-e294. PubMed ID: 29377371
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicine. Drug trial offers uncertain start in race to save children with progeria.
    Couzin-Frankel J
    Science; 2012 Sep; 337(6102):1594-5. PubMed ID: 23019622
    [No Abstract]   [Full Text] [Related]  

  • 19. Progeria: a paradigm for translational medicine.
    Gordon LB; Rothman FG; López-Otín C; Misteli T
    Cell; 2014 Jan; 156(3):400-7. PubMed ID: 24485450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation.
    Verstraeten VL; Broers JL; van Steensel MA; Zinn-Justin S; Ramaekers FC; Steijlen PM; Kamps M; Kuijpers HJ; Merckx D; Smeets HJ; Hennekam RC; Marcelis CL; van den Wijngaard A
    Hum Mol Genet; 2006 Aug; 15(16):2509-22. PubMed ID: 16825282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.